The U.S. Food and Drug Administration (FDA) has approved Allergan’s supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for the maintenance treatment of adults with schizophrenia.    The success of VRAYLAR in the maintenance treatment of schizophrenia was based on an up to 72-week, multinational, double-blind, placebo-controlled, randomized withdrawal study in the prevention of relapse in adult patients with schizophrenia. The study included a 20-week open-label phase wher...